{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T03:52:13Z","timestamp":1783569133012,"version":"3.55.0"},"reference-count":16,"publisher":"The Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:p>Reversal of cardiac fibrosis is a major determinant of the salutary effects of mineralocorticoid receptor antagonists in heart failure. Recently, R-fadrozole was coined as an aldosterone biosynthesis inhibitor, offering an appealing alternative to mineralocorticoid receptor antagonists to block aldosterone action. The present study aimed to evaluate the effects of R- and S-fadrozole on plasma aldosterone and urinary aldosterone excretion rate and to compare their effectiveness vs. the mineralocorticoid receptor antagonist potassium canrenoate to reverse established cardiac fibrosis. Male lean spontaneously hypertensive heart failure (SHHF) rats (40 wk) were treated for 8 wk by sc infusions of low (0.24 mg\/kg\u00b7d) or high (1.2 mg\/kg\u00b7d) doses of R- or S-fadrozole or by potassium canrenoate via drinking water (7.5 mg\/kg\u00b7d). At the high dose, plasma aldosterone levels were decreased similarly by R- and S-fadrozole, whereas urinary aldosterone excretion rate was reduced only by S-fadrozole. In contrast, whereas at the high dose, R-fadrozole effectively reversed preexistent left ventricular interstitial fibrosis by 50% (vs. 42% for canrenoate), S-fadrozole was devoid of an antifibrotic effect. The low doses of the fadrozole enantiomers did not change cardiac fibrosis or plasma aldosterone but similarly reduced urinary aldosterone excretion rate. In conclusion, R-fadrozole may possess considerable therapeutic merit because of its potent antifibrotic actions in the heart. However, the observed discordance between the aldosterone-lowering and antifibrotic effects of the fadrozole enantiomers raises some doubt about the mechanism by which R-fadrozole diminishes cardiac collagen and about the generality of the concept of lowering aldosterone levels to treat the diseased heart.<\/jats:p>","DOI":"10.1210\/en.2007-0584","type":"journal-article","created":{"date-parts":[[2007,9,21]],"date-time":"2007-09-21T00:48:56Z","timestamp":1190335736000},"page":"28-31","source":"Crossref","is-referenced-by-count":18,"title":["Fadrozole Reverses Cardiac Fibrosis in Spontaneously Hypertensive Heart Failure Rats: Discordant Enantioselectivity Versus Reduction of Plasma Aldosterone"],"prefix":"10.1210","volume":"149","author":[{"given":"Monica","family":"Minnaard-Huiban","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology (M.M-H., J.M.A,E., I.P.E.B., G.M.S.C., H.v.E., E.R., H.C.J.O., J.F.M.S., J.J.R.H.), Cardiovascular Research Institute, University of Maastricht, 6200 MD Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith M. A.","family":"Emmen","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology (M.M-H., J.M.A,E., I.P.E.B., G.M.S.C., H.v.E., E.R., H.C.J.O., J.F.M.S., J.J.R.H.), Cardiovascular Research Institute, University of Maastricht, 6200 MD Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Roumen","sequence":"first","affiliation":[{"name":"Biomodeling and Bioinformatics (L.R., K.P., P.A.J.H.), Department of Biomedical Engineering, Eindhoven University of Technology, 5600 MB Eindhoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona P. E.","family":"Beugels","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology (M.M-H., J.M.A,E., I.P.E.B., G.M.S.C., H.v.E., E.R., H.C.J.O., J.F.M.S., J.J.R.H.), Cardiovascular Research Institute, University of Maastricht, 6200 MD Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge\u0301raldine M. S.","family":"Cohuet","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology (M.M-H., J.M.A,E., I.P.E.B., G.M.S.C., H.v.E., E.R., H.C.J.O., J.F.M.S., J.J.R.H.), Cardiovascular Research Institute, University of Maastricht, 6200 MD Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helma","family":"van Essen","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology (M.M-H., J.M.A,E., I.P.E.B., G.M.S.C., H.v.E., E.R., H.C.J.O., J.F.M.S., J.J.R.H.), Cardiovascular Research Institute, University of Maastricht, 6200 MD Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline","family":"Ruijters","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology (M.M-H., J.M.A,E., I.P.E.B., G.M.S.C., H.v.E., E.R., H.C.J.O., J.F.M.S., J.J.R.H.), Cardiovascular Research Institute, University of Maastricht, 6200 MD Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Pieterse","sequence":"first","affiliation":[{"name":"Biomodeling and Bioinformatics (L.R., K.P., P.A.J.H.), Department of Biomedical Engineering, Eindhoven University of Technology, 5600 MB Eindhoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A. J.","family":"Hilbers","sequence":"first","affiliation":[{"name":"Biomodeling and Bioinformatics (L.R., K.P., P.A.J.H.), Department of Biomedical Engineering, Eindhoven University of Technology, 5600 MB Eindhoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry C. J.","family":"Ottenheijm","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology (M.M-H., J.M.A,E., I.P.E.B., G.M.S.C., H.v.E., E.R., H.C.J.O., J.F.M.S., J.J.R.H.), Cardiovascular Research Institute, University of Maastricht, 6200 MD Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Plate","sequence":"first","affiliation":[{"name":"NV Organon (R.P., M.E.d.G.), R&D Laboratories, 5340 BH Oss, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel E.","family":"de Gooyer","sequence":"first","affiliation":[{"name":"NV Organon (R.P., M.E.d.G.), R&D Laboratories, 5340 BH Oss, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos F. M.","family":"Smits","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology (M.M-H., J.M.A,E., I.P.E.B., G.M.S.C., H.v.E., E.R., H.C.J.O., J.F.M.S., J.J.R.H.), Cardiovascular Research Institute, University of Maastricht, 6200 MD Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J. Rob","family":"Hermans","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology (M.M-H., J.M.A,E., I.P.E.B., G.M.S.C., H.v.E., E.R., H.C.J.O., J.F.M.S., J.J.R.H.), Cardiovascular Research Institute, University of Maastricht, 6200 MD Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2007,9,20]]},"reference":[{"key":"2020071612255851900_R1","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1210\/jc.2003-030490","article-title":"50th Anniversary of aldosterone.","volume":"88","author":"Williams","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612255851900_R2","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.","volume":"82","author":"Swedberg K","year":"1990","journal-title":"Circulation"},{"key":"2020071612255851900_R3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2020071612255851900_R4","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2020071612255851900_R5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1365-2125.1999.00954.x","article-title":"Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?","volume":"47","author":"Struthers","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"2020071612255851900_R6","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"2020071612255851900_R7","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1161\/CIRCULATIONAHA.105.571653","article-title":"Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study.","volume":"112","author":"Izawa","year":"2005","journal-title":"Circulation"},{"key":"2020071612255851900_R8","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","article-title":"Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage.","volume":"111","author":"Fiebeler","year":"2005","journal-title":"Circulation"},{"key":"2020071612255851900_R9","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/01.hjh.0000226205.65442.f2","article-title":"Investigation of aldosterone-synthase inhibition in rats.","volume":"24","author":"Menard","year":"2006","journal-title":"J Hypertens"},{"key":"2020071612255851900_R10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/01.hjh.0000226183.98439.b3","article-title":"Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?","volume":"24","author":"Menard","year":"2006","journal-title":"J Hypertens"},{"key":"2020071612255851900_R11","doi-asserted-by":"crossref","first-page":"H1775","DOI":"10.1152\/ajpheart.00305.2002","article-title":"Structural, functional, and molecular characterization of the SHHF model of heart failure","volume":"283","author":"Heyen","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2020071612255851900_R12","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1021\/jm00106a038","article-title":"Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease.","volume":"34","author":"Browne","year":"1991","journal-title":"J Med Chem"},{"key":"2020071612255851900_R13","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1124\/jpet.301.2.672","article-title":"Pharmacokinetic advantage of intrapericardially applied substances in the rat.","volume":"301","author":"Hermans","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"2020071612255851900_R14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/HJH.0b013e3280102bff","article-title":"Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age.","volume":"25","author":"Baumann","year":"2007","journal-title":"J Hypertens"},{"key":"2020071612255851900_R15","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000064344.00173.44","article-title":"Is altered adrenal steroid biosynthesis a key intermediate phenotype in hypertension?","volume":"41","author":"Connell","year":"2003","journal-title":"Hypertension"},{"key":"2020071612255851900_R16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1152\/physrev.1999.79.1.215","article-title":"Molecular mechanisms of myocardial remodeling.","volume":"79","author":"Swynghedauw","year":"1999","journal-title":"Physiol Rev"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/149\/1\/28\/8991463\/endo0028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/149\/1\/28\/8991463\/endo0028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T20:12:48Z","timestamp":1594930368000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/149\/1\/28\/2454879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,20]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2007-0584","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,20]]}}}